ATE373827T1 - Kombination von markern für diabetes typ 1 und 2 - Google Patents
Kombination von markern für diabetes typ 1 und 2Info
- Publication number
- ATE373827T1 ATE373827T1 AT05014522T AT05014522T ATE373827T1 AT E373827 T1 ATE373827 T1 AT E373827T1 AT 05014522 T AT05014522 T AT 05014522T AT 05014522 T AT05014522 T AT 05014522T AT E373827 T1 ATE373827 T1 AT E373827T1
- Authority
- AT
- Austria
- Prior art keywords
- markers
- risk
- cardiovascular complication
- suffering
- diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 abstract 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102400001263 NT-proBNP Human genes 0.000 abstract 1
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract 1
- 102000004571 Natriuretic peptide Human genes 0.000 abstract 1
- 108010082093 Placenta Growth Factor Proteins 0.000 abstract 1
- 102100035194 Placenta growth factor Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000000692 natriuretic peptide Substances 0.000 abstract 1
- 230000010118 platelet activation Effects 0.000 abstract 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04015935 | 2004-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE373827T1 true ATE373827T1 (de) | 2007-10-15 |
Family
ID=35541816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05014522T ATE373827T1 (de) | 2004-07-07 | 2005-07-05 | Kombination von markern für diabetes typ 1 und 2 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7960123B2 (de) |
| JP (1) | JP4272642B2 (de) |
| AT (1) | ATE373827T1 (de) |
| CA (1) | CA2511269A1 (de) |
| DE (1) | DE602005002500T2 (de) |
| ES (1) | ES2294598T3 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| EP1962096B1 (de) * | 2002-11-16 | 2012-07-18 | Siemens Healthcare Diagnostics Products GmbH | SCD40L, PAPP-A und plazentaler-Wachstumsfaktor (PIGF) als biochemische Markerkombination bei kardiovaskulären Erkrankungen |
| DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
| ES2344993T3 (es) * | 2006-03-24 | 2010-09-13 | F. Hoffmann-La Roche Ag | Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos. |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| WO2008017306A1 (en) * | 2006-08-07 | 2008-02-14 | Antibodyshop A/S | Diagnostic test to exclude significant renal injury |
| ATE476665T1 (de) * | 2006-09-20 | 2010-08-15 | Hoffmann La Roche | Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion |
| EP1970709B1 (de) * | 2007-03-06 | 2013-07-10 | Roche Diagnostics GmbH | Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs |
| WO2009004443A2 (en) * | 2007-07-04 | 2009-01-08 | Medizinische Universität Wien | Compositions for the detection of gene expression in diabetic microangiopathy |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2120051B1 (de) * | 2008-05-13 | 2011-08-31 | Roche Diagnostics GmbH | Mittel und Verfahren zur Prognose von Nierenversagen bei Diabetikern auf Basis des plazentalen Wachstumsfaktors und löslichem Flt-1 |
| WO2009141357A1 (en) * | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| ES2549460T3 (es) | 2009-11-03 | 2015-10-28 | F. Hoffmann-La Roche Ag | NT-pro ANP y sFlt-1 para la diferenciación entre los eventos isquémicos y circulatorios |
| CA2780301A1 (en) * | 2009-11-13 | 2011-05-19 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
| US8602996B2 (en) | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| JP2015510416A (ja) | 2012-01-31 | 2015-04-09 | カーディアック ペースメイカーズ， インコーポレイテッド | バイオマーカーパネルデータを使用して、心臓再同期装置／治療を制御するシステム及び方法 |
| US20130196870A1 (en) * | 2012-01-31 | 2013-08-01 | Medical University Of South Carolina | Systems and methods using biomarker panel data |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| US10018591B2 (en) * | 2012-06-11 | 2018-07-10 | Preventage Healthcare, Llc | Methods for improving diabetes management |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| WO2021062298A1 (en) * | 2019-09-27 | 2021-04-01 | Arterez, Inc. | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
| CN110794135A (zh) * | 2019-10-31 | 2020-02-14 | 安徽大千生物工程有限公司 | Gpbb胶乳增强比浊法检测试剂盒及其制备使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| JPH08245424A (ja) * | 1995-03-06 | 1996-09-24 | Toagosei Co Ltd | 糖尿病性腎症診断剤 |
| DE60025526T2 (de) * | 1999-11-16 | 2006-08-24 | Genentech, Inc., South San Francisco | Elisa für vegf |
| EP1962096B1 (de) * | 2002-11-16 | 2012-07-18 | Siemens Healthcare Diagnostics Products GmbH | SCD40L, PAPP-A und plazentaler-Wachstumsfaktor (PIGF) als biochemische Markerkombination bei kardiovaskulären Erkrankungen |
| EP1562990B1 (de) * | 2002-11-18 | 2010-07-21 | Syn X Pharma, Inc. | Polyklonaler-monoklonaler-elisa-assay zum nachweis von n-terminalem probnp |
-
2005
- 2005-06-30 CA CA002511269A patent/CA2511269A1/en not_active Abandoned
- 2005-07-05 AT AT05014522T patent/ATE373827T1/de active
- 2005-07-05 DE DE602005002500T patent/DE602005002500T2/de not_active Expired - Lifetime
- 2005-07-05 ES ES05014522T patent/ES2294598T3/es not_active Expired - Lifetime
- 2005-07-06 US US11/175,933 patent/US7960123B2/en not_active Expired - Fee Related
- 2005-07-06 JP JP2005197634A patent/JP4272642B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7960123B2 (en) | 2011-06-14 |
| ES2294598T3 (es) | 2008-04-01 |
| CA2511269A1 (en) | 2006-01-07 |
| DE602005002500T2 (de) | 2008-06-12 |
| US20060008829A1 (en) | 2006-01-12 |
| JP4272642B2 (ja) | 2009-06-03 |
| JP2006030183A (ja) | 2006-02-02 |
| DE602005002500D1 (de) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE373827T1 (de) | Kombination von markern für diabetes typ 1 und 2 | |
| ATE364177T1 (de) | Kombinationen von markern zum nachweis von typ 1 und 2 diabetes | |
| ATE469353T1 (de) | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen | |
| ATE403157T1 (de) | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung | |
| Gessler et al. | Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery | |
| CN101568833B (zh) | 使用MR-proADM的糖尿病诊断和风险分级 | |
| JP2010513879A5 (de) | ||
| CN101646945A (zh) | 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层 | |
| Kim et al. | Effects of marathon running on cardiac markers and endothelin-1 in EIH athletes | |
| JP2008046129A5 (de) | ||
| RU2014145259A (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| MX339184B (es) | Panel multimarcador para hipertrofia ventricular izquierda. | |
| WO2009087190A1 (en) | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 | |
| JP2006502203A5 (de) | ||
| PT1849009E (pt) | Utilização de hormonas cardíacas para avaliar um risco cardiovascular em relação à administração de fármacos anti-inflamatórios | |
| ES2549460T3 (es) | NT-pro ANP y sFlt-1 para la diferenciación entre los eventos isquémicos y circulatorios | |
| CA2567738A1 (en) | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication | |
| Okura et al. | Undercarboxylated osteocalcin is a biomarker of carotid calcification in patients with essential hypertension | |
| US9482678B1 (en) | Method for measurement of bioavailable testosterone | |
| JP2012516436A5 (de) | ||
| ATE476665T1 (de) | Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion | |
| ES2657087T3 (es) | Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas | |
| İyidir et al. | Evaluation of ambulatory arterial stiffness index in hyperthyroidism | |
| Abrahams et al. | Use of the WHO hemoglobin color scale in family welfare clinics in India | |
| WO2013045570A1 (en) | Sflt1 in subjects during or immediately after physical exercise |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1615036 Country of ref document: EP |